# Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC

> **NCT03289819** · PHASE2 · COMPLETED · sponsor: **Institut fuer Frauengesundheit** · enrollment: 53 (actual)

## Conditions studied

- Malignant Neoplasm of Breast

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** nab-paclitaxel
- **DRUG:** Epirubicin
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT03289819
- **Lead sponsor:** Institut fuer Frauengesundheit
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-23
- **Primary completion:** 2020-08-27
- **Final completion:** 2021-01-22
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2021-04-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03289819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03289819, "Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03289819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*